Epstein–Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era | Zendy

Julien Lupo | Zendy; Raphaële Germi | Zendy; Rémi Lancar | Zendy; Michèle Algarté-Génin | Zendy; Houria Hendel-Chavez | Zendy; Yassine Taoufik | Zendy; Nicolas Mounier | Zendy; Marialuisa Partisani | Zendy; Fabrice Bonnet | Zendy; Marie-Caroline Meyohas | Zendy; B. Marchou | Zendy; Touyana Semanova | Zendy; Sophie Prévôt | Zendy; Dominique Costagliola | Zendy; Patrice Morand | Zendy; Caroline Besson | Zendy

Open Access

Epstein–Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era

Author(s) -

Julien Lupo,

Raphaële Germi,

Rémi Lancar,

Michèle Algarté-Génin,

Houria Hendel-Chavez,

Yassine Taoufik,

Nicolas Mounier,

Marialuisa Partisani,

Fabrice Bonnet,

Marie-Caroline Meyohas,

B. Marchou,

Touyana Semanova,

Sophie Prévôt,

Dominique Costagliola,

Patrice Morand,

Caroline Besson

Publication year - 2019

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0000000000002129

Subject(s) - medicine , serology , lymphoma , interquartile range , viral load , immunology , antibody , epstein–barr virus , chemotherapy , gastroenterology , virus , whole blood , virology

Epstein-Barr virus (EBV) has been implicated in lymphomagenesis of HIV-related classical Hodgkin lymphoma (HIV-cHL). The utility of EBV molecular and serological biomarkers has scarcely been examined in HIV-cHL in the recent combined antiretroviral therapy (cART) era.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore